<DOC>
	<DOC>NCT00353080</DOC>
	<brief_summary>To confirm the superiority of 5 mg daily risedronate as compared to placebo in maintaining or increasing bone mass in lumbar spine in osteopenic postmenopausal women To confirm the efficacy of 5 mg daily risedronate in osteopenic postmenopausal women in maintaining or increasing bone mass in proximal femur and decreasing bone resorption To confirm general safety of 5 mg daily risedronate as compared to placebo</brief_summary>
	<brief_title>Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Ambulatory, healthy postmenopausal women with Natural menopause and more than 5 years after their last menstrual period or surgical menopause and more than 5 years after surgery osteopenia (lumbar spine T score between 1 and 2.5 SD below the mean value in normal young women). With at least one risk factor for osteoporosis Women who have received hormone replacement therapy (with estrogen and/or progestogen and/or androgen) or raloxifene within 3 months before visit 2 or calcitonin or calcitriol within 4 weeks before visit 2</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Prevention of postmenopausal osteoporosis</keyword>
</DOC>